Hypothalamic control of energy metabolism via the autonomic nervous system

Annals of the New York Academy of Sciences

Volumn 1212, Issue , 2010, Pages 114-129

  Kalsbeek, A ^a,b   Bruinstroop, E ^a   Yi, C X ^a,b   Klieverik, L P ^a   La Fleur, S E ^a   Fliers, E ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Circadian; Insulin; Neuropeptide Y; Orexin; PACAP; Thyroid hormone

Indexed keywords

GLUCOSE; LEPTIN RECEPTOR;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; BIOLOGICAL RHYTHM; CIRCADIAN RHYTHM; ENERGY METABOLISM; FEEDBACK SYSTEM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HYPOTHALAMUS; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER METABOLISM; METABOLIC REGULATION; NONHUMAN; WHITE ADIPOSE TISSUE;

EID: 78649473630     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05800.x     Document Type: Article

References (166)

1. Buis, R.M. & A. Kalsbeek 2001. The day-night balance of everyday life: central and peripheral clocks interacting in the hypothalamus. Nat. Neurosci. Rev. 2: 521-526.
2. Kalsbeek, A. & R.M. Buis 2002. Output pathways of the mammalian suprachiasmatic nucleus: coding circadian time by transmitter selection and specific targeting. Cell Tissue Res. 309: 109-118.
3. Kalsbeek, A., R.M. Buis, J.J. Van Heerikhuize, et al 1992. Vasopressin containing neurons of the suprachiasmatic nuclei inhibit corticosterone release. Brain Res. 580: 62-67.
4. 1-antagonist. J. Neurosci. 16: 5555-5565.
5. Kalsbeek, A., J. Van Der Vliet & R.M. Buis 1996b. Decrease of endogenous vasopressin release necessary for expression of the circadian rise in plasma corticosterone: a reverse microdialysis study. J. Neuroendocrinol. 8: 299-307.
6. Buis, R.M., J. Wortel, J.J. Van Heerikhuize, et al 1999. Anatomical and functional demonstration of a multisynaptic suprachiasmatic nucleus adrenal (cortex) pathway. Eur. J. Neurosci. 11: 1535-1544.
7. Trudel, E. & C.W. Bourque 2010. Central clock excites vasopressin neurons by waking osmosensory afferents during late sleep. Nat. Neurosci. 13: 467-474.
8. Colwell, C.S. 2010. Preventing dehydration during sleep. Nat. Neurosci. 13: 403-404.
9. Kalsbeek, A., S.E. La Fleur, C. Van Heijningen & R.M. Buijs 2004. Suprachiasmatic GABAergic inputs to the paraventricular nucleus control plasma glucose concentrations in the rat via sympathetic innervation of the liver. J. Neurosci. 24: 7604-7613.
10. Kalsbeek, A., M. Ruiter, S.E. La Fleur, et al 2006. The hypothalamic clock and its control of glucose homeostasis. Prog. Brain Res. 153: 283-307.
11. Cailotto, C., S.E. La Fleur, C. Van Heijningen, et al 2005. The suprachiasmatic nucleus controls the daily variation of plasma glucose via the autonomic output to the liver: are the clock genes involved? Eur. J. Neurosci. 22: 2531-2540.
12. Cailotto, C., C. Van Heijningen, J. Van Der Vliet, et al 2008. Daily rhythms in metabolic liver enzymes and plasma glucose require a balance in the autonomic output to the liver. Endocrinology 149: 1914-1925.
13. Kalsbeek, A., E. Foppen, I. Schalij, et al 2008. Circadian control of the daily plasma glucose rhythm: an interplay of GABA and glutamate. PLoS One 3: e3194.
14. Yi, C.X., M.J. Serlie, M.T. Ackermans, et al 2009. A major role for perifornical orexin neurons in the control of glucose metabolism in rats. Diabetes. 58: 1998-2005.
15. Yi, C.-X., N. Sun, M.T. Ackermans, et al 2010. Pituitary adenylate cyclase-activating polypeptide stimulates glucose production through glycogenolysis and via the hepatic sympathetic innervation in rats. Diabetes. 59: 1591-1600.
16. Campfield, L.A., F.J. Smith, Y. Guisez, et al 1995. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269: 546-549.
17. Obici, S., Z. Feng, G. Karkanias, D.G. Baskin & L. Rossetti 2002a. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat. Neurosci. 5: 566-572.
18. Obici, S., B.B. Zhang, G. Karkanias & L. Rossetti 2002b. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat. Med. 8: 1376-1382.
19. Van Den Hoek, A.M., C. Van Heijningen, J.P. Schroder-Van Der Elst, et al 2008. Intracerebroventricular administration of NPY hampers insulin action to suppress endogenous glucose production via the sympathetic nervous system. Diabetes 57: 2304-2310.
20. Klieverik, L.P., S.F. Janssen, A. Van Riel, et al 2009. Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver. Proc. Natl. Acad. Sci. USA 106: 5966-5971.
21. Fliers, E., L.P. Klieverik & A. Kalsbeek 2010. Novel neural pathways for metabolic effects of thyroid hormone. Tr. Endocrinol. Metab. 21: 230-236.
22. Musatov, S., W. Chen, D.W. Pfaff, C.V. Mobbs, et al 2007. Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proc. Natl. Acad. Sci. USA 104: 2501-2506.
23. Clegg, D.J., L.M. Brown, S.C. Woods & S.C. Benoit 2006. Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes 55: 978-987.
24. Marks, J.L. & K. Waite 1997. Intracerebroventricular neuropeptide Y acutely influences glucose metabolism and insulin sensitivity in the rat. J. Neuroendocrinol. 9: 99-103.
25. Marks, J.L. & K. Waite 1996. Some acute effects of intracerebroventricular neuropeptide Y on insulin secretion and glucose metabolism in the rat. J. Neuroendocrinol. 8: 507-513.
26. Van Den Hoek, A.M., P.J. Voshol, B.N. Karnekamp, et al 2004. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes 53: 2529-2534.
27. Unger, J., T.H. McNeill, R.T. Moxley III, et al 1989. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience 31: 143-157.
28. Schwartz, M.W., J.L. Marks, A.J. Sipols, et al 1991. Central insulin administration reduces neuropeptide Y mRNA expression in the arcuate nucleus of food-deprived lean (Fa/Fa) but not obese (fa/fa) Zucker rats. Endocrinology 128: 2645-2647.
29. Van Den Top, M. & D. Spanswick 2006. Integration of metabolic stimuli in the hypothalamic arcuate nucleus. Prog. Brain Res. 153: 141-154.
30. Hu, Y. & J.C. Dunbar 1997. Intracerebroventricular administration of NPY increases sympathetic tone selectively in vascular beds. Brain Res. Bull. 44: 97-103.
31. Van Dijk, G., A.E. Bottone, J.H. Strubbe & A.B. Steffens 1994. Hormonal and metabolic effects of paraventricular hypothalamic administration of neuropeptide Y during rest and feeding. Brain Res. 660: 96-103.
32. Egawa, M., H. Yoshimatsu & G.A. Bray 1994. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am. J. Physiol. 260: R328-R334.
33. Pocai, A., T.K. Lam, R. Gutierrez-Juarez, et al 2005. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434: 1026-1031.
34. Zarjevski, N., I. Cusin, R. Vettor, et al 1993. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 133: 1753-1758.
35. Baran, K., E. Preston, D. Wilks, et al 2002. Chronic central melanocortin-4 receptor antagonism and central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways. Diabetes 51: 152-158.
36. Mashiko, S., A. Ishihara, H. Iwaasa, et al 2003. Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY. Endocrinology 144: 1793-1801.
37. Sainsbury, A., I. Cusin, F. Rohner-Jeanrenaud & B. Jeanrenaud 1997. Adrenalectomy prevents the obesity syndrome produced by chronic central neuropeptide Y infusion in normal rats. Diabetes. 46: 209-214.
38. Zakrzewska, K.E., A. Sainsbury, I. Cusin, et al 1999. Selective dependence of intracerebroventricular neuropeptide Y-elicited effects on central glucocorticoids. Endocrinology 140: 3183-3187.
39. Stafford, J.M., F. Yu, R. Printz, et al 2008. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Diabetes 57: 1482-1490.
40. Ollmann, M.M., B.D. Wilson, Y.K. Yang, et al 1997. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278: 135-138.
41. Fan, W., D.M. Dinulescu, A.A. Butler, et al 2000. The central melanocortin system can directly regulate serum insulin levels. Endocrinology 141: 3072-3079.
42. Banno, R., H. Arima, M. Hayashi, et al 2007. Central administration of melanocortin agonist increased insulin sensitivity in diet-induced obese rats. FEBS Lett. 581: 1131-1136.
43. Obici, S., Z. Feng, J. Tan, et al 2001. Central melanocortin receptors regulate insulin action. J. Clin. Invest. 108: 1079-1085.
44. Heijboer, A.C., A.M. Van Den Hoek, H. Pijl, et al 2005. Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice. Diabetologia 48: 1621-1626.
45. Mizuno, T.M., K.A. Kelley, G.M. Pasinetti, et al 2003. Transgenic neuronal expression of proopiomelanocortin attenuates hyperphagic response to fasting and reverses metabolic impairments in leptin-deficient obese mice. Diabetes 52: 2675-2683.
46. Lee, M., A. Kim, S.C. Chua, Jr., S. Obici & S.L. Wardlaw 2007. Transgenic MSH overexpression attenuates the metabolic effects of a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 293: E121-31.
47. Farooqi, S. 2009. Obesity genes-it's all about the parents! Cell Metab. 9: 487-488.
48. Gutierrez-Juarez, R., S. Obici & L. Rossetti 2004. Melanocortin-independent effects of leptin on hepatic glucose fluxes. J. Biol. Chem. 279: 49704-49715.
49. Toda, C., T. Shiuchi, S. Lee, et al 2009. Distinct effects of leptin and a melanocortin receptor agonist injected into medial hypothalamic nuclei on glucose uptake in peripheral tissues. Diabetes 58: 2757-2765.
50. Liu, L., G.B. Karkanias, J.C. Morales, et al 1998. Intracerebroventricular leptin regulates hepatic but not peripheral glucose fluxes. J. Biol. Chem. 273: 31160-31167.
51. Rossetti, L., D. Massillon, N. Barzilai, et al 1997. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J. Biol. Chem. 272: 27758-27763.
52. German, J., F. Kim, G.J. Schwartz, et al 2009. Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology 15: 4502-4511.
53. Huo, L., K. Gamber, S. Greeley, et al 2009. Leptin-dependent control of glucose balance and locomotor activity by POMC neurons. Cell Metab. 9: 537-547.
54. Hill, J.W., C.F. Elias, M. Fukuda, et al 2010. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab. 11: 286-297.
55. Adage, T., A.J. Scheurink, S.F. De Boer, et al 2001. Hypothalamic, metabolic, and behavioral responses to pharmacological inhibition of CNS melanocortin signaling in rats. J. Neurosci. 21: 3639-3645.
56. Nogueiras, R., P. Wiedmer, D. Perez-Tilve, et al 2007. The central melanocortin system directly controls peripheral lipid metabolism. J. Clin. Invest. 117: 3475-3488.
57. Jones, B.H., J.H. Kim, M.B. Zemel, et al 1996. Upregulation of adipocyte metabolism by agouti protein: possible paracrine actions in yellow mouse obesity. Am. J. Physiol. 270: E192-E196.
58. Poritsanos, N.J., D. Wong, M.E. Vrontakis & T.M. Mizuno 2008. Regulation of hepatic PPARgamma2 and lipogenic gene expression by melanocortin. Biochem. Biophys. Res. Commun. 376: 384-388.
59. Albarado, D.C., J. McClaine, J.M. Stephens, et al 2004. Impaired coordination of nutrient intake and substrate oxidation in melanocortin-4 receptor knockout mice. Endocrinology 145: 243-252.
60. Lin, J., Y.H. Choi, D.L. Hartzell, C. Li, et al 2003. CNS melanocortin and leptin effects on stearoyl-CoA desaturase-1 and resistin expression. Biochem. Biophys. Res. Commun. 311: 324-328.
61. Barb, C.R., G.J. Hausman, R. Rekaya, et al 2010. Gene expression in hypothalamus, liver and adipose tissues and food intake response to melanocortin-4 receptor (MC4R) agonist in pigs expressing MC4R mutations. Physiol. Genomics. In press.
62. Chemelli, R.M., J.T. Willie, C.M. Sinton, et al 1999. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451.
63. De Lecea, L., T.S. Kilduff, C. Peyron, et al 1998. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 95: 322-327.
64. Kilduff, T.S., E.S. Lein, H. De La Iglesia, et al 2008. New developments in sleep research: molecular genetics, gene expression, and systems neurobiology. J. Neurosci. 28: 11814-11818.
65. Shiuchi, T., M.S. Haque, S. Okamoto, et al 2009. Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab. 10: 466-480.
66. Wang, Y., K. Seburn, L. Bechtel, et al 2006. Defective carbohydrate metabolism in mice homozygous for the tubby mutation. Physiol. Genomics. 27: 131-140.
67. Van Den Top, M., M.F. Nolan, K. Lee, et al 2003. Orexins induce increased excitability and synchronisation of rat sympathetic preganglionic neurones. J. Physiol. 549: 809-821.
68. Alam, M.N., S. Kumar, T. Bashir, et al 2005. GABA-mediated control of hypocretin- but not melanin-concentrating hormone-immunoreactive neurones during sleep in rats. J. Physiol. 563: 569-582.
69. Zhang, S., J.M. Zeitzer, Y. Yoshida, et al 2004. Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release. Sleep 27: 619-627.
70. Spiegel, K., K. Knutson, R. Leproult, et al 2005. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J. Appl. Physiol. 99: 2008-2019.
71. Nilsson, P.M., M. Roost, G. Engstrom, et al 2004. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care 27: 2464-2469.
72. Meisinger, C., M. Heier & H. Loewel 2005. Sleep disturbance as a predictor of type 2 diabetes mellitus in men and women from the general population. Diabetologia 48: 235-241.
73. Martins, P.J., M.S. Marques, S. Tufik & V. D'Almeida 2010. Orexin activation precedes increased NPY expression, hyperphagia, and metabolic changes in response to sleep deprivation. Am. J. Physiol. Endocrinol. Metab. 298: E726-E734.
74. Yoshida, Y., N. Fujiki, T. Nakajima, et al 2001. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur. J. Neurosci. 14: 1075-1081.
75. Pedrazzoli, M., V. D'Almeida, P.J. Martins, et al 2004. Increased hypocretin-1 levels in cerebrospinal fluid after REM sleep deprivation. Brain Res. 995: 1-6.
76. Kalsbeek, A., C.X. Yi, S.E. La Fleur & E. Fliers 2010. The hypothalamic clock and its control of glucose homeostasis. Tr. Endocrinol. Metab. 21: 402-410.
77. Poli, F., G. Plazzi, D.G. Di, et al 2009. Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Sleep 32: 1491-1497.
78. Funato, H., A.L. Tsai, J.T. Willie, et al 2009. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab. 9: 64-76.
79. Yamanaka, A., T. Sakurai, T. Katsumoto, et al 1999. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res. 849: 248-252.
80. Shen, J., M. Tanida, J.F. Yao, A. Niijima & K. Nagai 2008. Biphasic effects of orexin-A on autonomic nerve activity and lipolysis. Neurosci. Lett. 444: 166-171.
81. Shimada, M., N.A. Tritos, B.B. Lowell, et al 1998. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396: 670-674.
82. Qu, D., D.S. Ludwig, S. Gammeltoft, et al 1996. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380: 243-247.
83. Sawchenko, P.E. 1998. Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. J. Comp. Neurol. 402: 435-441.
84. Segal-Lieberman, G., R.L. Bradley, E. Kokkotou, et al 2003. Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc. Natl. Acad. Sci. USA 100: 10085-10090.
85. Ludwig, D.S., N.A. Tritos, J.W. Mastaitis, et al 2001. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J. Clin. Invest. 107: 379-386.
86. Mul, J.D., C.X. Yi, S.A. Van Den Berg, et al 2010. Pmch expression during early development is critical for normal energy homeostasis. Am. J. Physiol. Endocrinol. Metab. 298: E477-E488.
87. Ito, M., A. Gomori, A. Ishihara, et al 2003. Characterization of MCH-mediated obesity in mice. Am. J. Physiol. Endocrinol. Metab. 284: E940-E945.
88. Kowalski, T.J., B.D. Spar, B. Weig, et al 2006. Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice. Eur. J. Pharmacol. 535: 182-191.
89. Ito, M., A. Gomori, J. Suzuki, et al 2008. Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice. J Endocrinol. 198: 309-315.
90. Gomori, A., A. Ishihara, M. Ito, et al 2007. Blockade of MCH1 receptor signalling ameliorates obesity and related hepatic steatosis in ovariectomized mice. Br. J. Pharmacol. 151: 900-908.
91. Miyata, A., A. Arimura, R.R. Dahl, et al 1989. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164: 567-574.
92. Gray, S.L., K.J. Cummings, F.R. Jirik & N.M. Sherwood 2001. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol. Endocrinol. 15: 1739-1747.
93. Jamen, F., K. Persson, G. Bertrand, et al 2000. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J. Clin. Invest. 105: 1307-1315.
94. Nakata, M., D. Kohno, N. Shintani, et al 2004. PACAP deficient mice display reduced carbohydrate intake and PACAP activates NPY-containing neurons in the rat hypothalamic arcuate nucleus. Neurosci. Lett. 370: 252-256.
95. Morley, J.E., M. Horowitz, P.M. Morley & J.F. Flood 1992. Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in mice. Peptides 13: 1133-1135.
96. Mizuno, Y., K. Kondo, Y. Terashima, et al 1998. Anorectic effect of pituitary adenylate cyclase activating polypeptide (PACAP) in rats: lack of evidence for involvement of hypothalamic neuropeptide gene expression. J. Neuroendocrinol. 10: 611-616.
97. Mounien, L., J.C. Do Rego, P. Bizet, et al 2009. Pituitary Adenylate Cyclase-Activating Polypeptide inhibits food intake in mice through activation of the hypothalamic melanocortin system. Neuropsychopharmacology 34: 424-435.
98. Tanida, M., N. Shintani, Y. Morita, et al 2010. Regulation of autonomic nerve activities by central pituitary adenylate cyclase-activating polypeptide. Regul. Pept. 161: 73-80.
99. Hannibal, J. 2002. Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study. J. Comp. Neurol. 453: 389-417.
100. Borg, W.P., M.J. During, R.S. Sherwin, et al 1994. Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia. J. Clin. Invest. 93: 1677-1682.
101. Segal, J.P., N.R. Stallings, C.E. Lee, et al 2005. Use of laser-capture microdissection for the identification of marker genes for the ventromedial hypothalamic nucleus. J. Neurosci. 25: 4181-4188.
102. Agarwal, A., L.M. Halvorson & G. Legradi 2005. Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene. Mol. Brain Res. 138: 45-57.
103. Grinevich, V., A. Fournier & G. Pelletier 1997. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on corticotropin-releasing hormone (CRH) gene expression in the rat hypothalamic paraventricular nucleus. Brain Res. 773: 190-196.
104. Hammack, S.E., C.W. Roman, K.R. Lezak, et al 2010. Roles for Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Expression and Signaling in the Bed Nucleus of the Stria Terminalis (BNST) in Mediating the Behavioral Consequences of Chronic Stress. J. Mol. Neurosci. In press.
105. Tachibana, T., D. Oikawa, N. Adachi, et al 2007. Central administration of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide differentially regulates energy metabolism in chicks. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 147: 156-164.
106. Tomimoto, S., T. Ojika, N. Shintani, et al 2008. Markedly reduced white adipose tissue and increased insulin sensitivity in adcyap1-deficient mice. J. Pharmacol. Sci. 107: 41-48.
107. Martin, B., Y.K. Shin, C.M. White, et al 2010. Vasoactive intestinal peptide null mice demonstrate enhanced sweet taste preference, dysglycemia and reduced taste bud leptin receptor expression. Diabetes. 59: 1143-1152.
108. Bechtold, D.A., T.M. Brown, S.M. Luckman & H.D. Piggins 2008. Metabolic rhythm abnormalities in mice lacking VIP-VPAC2 signaling. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: R344-R351.
109. Nagai, N., H. Kajikawa, T. Sasaki, et al 1994. Hyperglycemic response to intracranial injection of vasoactive intestinal peptide. J. Clin. Biochem. Nutr. 17: 29-34.
110. Nagai, K., N. Nagai, K. Shimizu, et al 1996. SCN output drives the autonomic nervous system: with special reference to the autonomic function related to the regulation of glucose metabolism. Prog. Brain Res. 111: 253-272.
111. Nakagawa, H. & N. Okumura 2010. Coordinated regulation of circadian rhythms and homeostasis by the suprachiasmatic nucleus. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 86: 391-409.
112. Heuer, H., M.K. Schäfer, D. O'Donnell, et al 2000. Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J. Comp. Neurol. 428: 319-336.
113. Kabayama, Y., Y. Kato, K. Tojo, et al 1985. Central effects of DN1417, a novel TRH analog, on plasma glucose and catecholamines in conscious rats. Life Sci. 36: 1287-1294.
114. Marubashi, S., Y. Kunii, M. Tominaga & H. Sasaki 1988. Modulation of plasma glucose levels by thyrotropin-releasing hormone administered intracerebroventricularly in the rat. Neuroendocrinology 48: 640-644.
115. Ishiguro, T., A. Iguchi, Y. Kunoh, et al 1991. Relative contribution of nervous system and hormones to hyperglycemia induced by thyrotropin-releasing hormone in fed rats. Neuroendocrinology 54: 1-6.
116. Yamada, M., Y. Saga, N. Shibusawa, et al 1997. Tertiary hypothyroidism and hyperglycemia in mice with targeted disruption of the thyrotropin-releasing hormone gene. Proc. Natl. Acad. Sci. USA 94: 10862-10867.
117. Yoneda, M., T. Kono, H. Watanobe, et al 2005. Central thyrotropin-releasing hormone increases hepatic cyclic AMP through vagal-cholinergic and prostaglandin-dependent pathways in rats. Peptides 26: 1573-1579.
118. Raybould, H.E., L.J. Jakobsen, D. Novin & Y. Taché 1989. TRH stimulation and L-glutamic acid inhibition of proximal gastric motor activity in the rat dorsal vagal complex. Brain Res. 495: 319-328.
119. Morrow, N.S., D. Novin & T. Garrick 1994. Microinjection of Thyrotropin-Releasing Hormone in the paraventricular nucleus of the hypothalamus stimulates gastric contractility. Brain Res. 644: 243-250.
120. Yang, H. & Y. Taché 1994. Prepro-TRH-(160-169) potentiates gastric acid secretion stimulated by TRH microinjected into the dorsal motor nucleus of the vagus. Neurosci. Lett. 174: 43-46.
121. Lynn, R.B., M.S. Kreider & R.R. Miselis 1991. Thyrotropin-releasing hormone-immunoreactive projections to the dorsal motor nucleus and the nucleus of the solitary tract of the rat. J. Comp. Neurol. 311: 271-288.
122. Hökfelt, T., K. Fuxe, O. Johansson, et al 1975. Distribution of thyrotropin-releasing hormone (TRH) in the central nervous system as revealed with immunohistochemistry. Eur. J. Pharmacol. 34: 389-392.
123. Manaker, S. & G. Rizio 1989. Autoradiographic localization of thyrotropin-releasing hormone and substance P receptors in the rat dorsal vagal complex. J. Comp. Neurol. 290: 516-526.
124. Lechan, R.M., S.B. Snapper & I.M.D. Jackson 1983. Evidence that spinal cord thyrotropin-releasing hormone is independent of the paraventricular nucleus. Neurosci. Lett. 43: 61-65.
125. Hirsch, M.D. & C.J. Helke 1988. Bulbospinal thryrotropin-releasing hormone projections to the intermediolateral cell column: a double fluorescence immunohistochemical-retrograde tracing study in the rat. Neuroscience 25: 625-637.
126. Wittmann, G., T. Fuzesi, Z. Liposits, et al 2009. Distribution and axonal projections of neurons coexpressing thyrotropin-releasing hormone and urocortin 3 in the rat brain. J. Comp. Neurol. 517: 825-840.
127. Westerhaus, M.J. & A.D. Loewy 1999. Sympathetic-related neurons in the preoptic region of the rat identified by viral transneuronal labeling. J. Comp. Neurol. 414: 361-378.
128. Jansen, A.S.P., M.W. Wessendorf & A.D. Loewy 1995. Transneuronal labeling of CNS neuropeptide and monoamine neurons after pseudorabies virus injections into the stellate ganglion. Brain Res. 683: 1-24.
129. Kalsbeek, A., E. Fliers, A.N. Franke, et al 2000. Functional connections between the suprachiasmatic nucleus and the thyroid gland as revealed by lesioning and viral tracing techniques in the rat. Endocrinology 141: 3832-3841.
130. Oppenheimer, J.H., H.L. Schwartz, J.T. Lane & M.P. Thompson 1991. Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J. Clin. Invest. 87: 125-132.
131. Klieverik, L.P., C.P. Coomans, E. Endert, et al 2009. Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. Endocrinology 150: 5639-5648.
132. Riedel, W. & S.L. Burke 1988. Selective autonomic nervous control of thyroid hormone and calcitonin secretion during metabolic and cardiorespiratory activation by intracisternal thyrotropin-releasing hormone (TRH). J. Auton. Nerv. Syst. 24: 157-173.
133. Hems, D.A., L.M. Rodrigues & P.D. Whitton 1978. Rapid stimulation by vasopressin, oxytocin and angiotensin II of glycogen degradation in hepatocyte suspensions. Biochem. J 172: 311-317.
134. Tanoue, A. 2009. New topics in vasopressin receptors and approach to novel drugs: effects of vasopressin receptor on regulations of hormone secretion and metabolisms of glucose, fat, and protein. J. Pharmacol. Sci. 109: 50-52.
135. Dunning, B.E., J.H. Moltz & C.P. Fawcett 1984. Modulation of insulin and glucagon secretion from the perfused rat pancreas by the neurohypophysial hormones and by desamino-D-arginine vasopressin (DDAVP). Peptides 5: 871-875.
136. Wideman, C.H. & H.M. Murphy 1993. Modulatory effects of vasopressin on glucose and protein metabolism during food-restriction stress. Peptides 14: 259-261.
137. Aoyagi, T., J. Birumachi, M. Hiroyama, et al 2007. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148: 2075-2084.
138. Fujiwara, Y., M. Hiroyama, A. Sanbe, et al 2007. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J. Physiol. 584: 235-244.
139. Kow, L.M. & D.W. Pfaff 1986. Vasopressin excites ventromedial hypothalamic glucose-responsive neurons in vitro. Physiol. Behav. 37: 153-158.
140. Yarkov, A., S. Montero, M. Lemus, et al 2001. Arginine-vasopressin in nucleus of the tractus solitarius induces hyperglycemia and brain glucose retention. Brain Res. 902: 212-222.
141. Hiroyama, M., T. Aoyagi, Y. Fujiwara, et al 2007. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol. Endocrinol. 21: 247-58.
142. Hiroyama, M., Y. Fujiwara, K. Nakamura, et al 2009. Altered lipid metabolism in vasopressin V1B receptor-deficient mice. Eur. J. Pharmacol. 602: 455-461.
143. Gilbey, M.P., J.H. Coote, S. Fleetwood-Walker & D.F. Peterson 1982. The influence of the paraventriculo-spinal pathway, and oxytocin and vasopressin on sympathetic preganglionic neurones. Brain Res. 251: 283-290.
144. Backman, S.B. & J.L. Henry 1984. Effects of oxytocin and vasopressin on thoracic sympathetic preganglionic neurones in the cat. Brain Res. Bull. 13: 679-684.
145. Arletti, R., A. Benelli & A. Bertolini 1989. Influence of oxytocin on feeding behavior in the rat. Peptides 10: 89-93.
146. Olson, B.R., M.D. Drutarosky, M.-S. Chow, et al 1991. Oxytocin and an oxytocin agonist administered centrally decrease food intake in rats. Peptides 12: 113-118.
147. Blevins, J.E., M.W. Schwartz & D.G. Baskin 2004. Evidence that paraventricular nucleus oxytocin neurons link hypothalamic leptin action to caudal brain stem nuclei controlling meal size. Am. J. Physiol. 287: R87-R96.
148. Buijs, R.M., S.J. Chun, A. Niijima, et al 2001. Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. J. Comp. Neurol. 431: 405-423.
149. Shi, H.F. & T.J. Bartness 2001. Neurochemical phenotype of sympathetic nervous system outflow from brain to white fat. Brain Res. Bull. 54: 375-385.
150. Oldfield, B.J., M.E. Giles, A. Watson, et al 2002. The neurochemical characterisation of hypothalamic pathways projecting polysynaptically to brown adipose tissue in the rat. Neuroscience 110: 515-526.
151. Stanley, S., S. Pinto, J. Segal, et al 2010. Identification of neuronal subpopulations that project from hypothalamus to both liver and adipose tissue polysynaptically. Proc. Natl. Acad. Sci. USA 107: 7024-7029.
152. Swaab, D.F., J.S. Purba & M.A. Hofman 1995. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J. Clin. Endocrinol. Metab. 80: 573-579.
153. Kublaoui, B.M., T. Gemelli, K.P. Tolson, et al 2008. Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice. Mol. Endocrinol. 22: 1723-1734.
154. Camerino, C. 2009. Low sympathetic tone and obese phenotype in oxytocin-deficient mice. Obesity (Silver Spring) 17: 980-984.
155. Takayanagi, Y., Y. Kasahara, T. Onaka, et al 2008. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport 19: 951-955.
156. Schaffler, A., N. Binart, J. Scholmerich & C. Buchler 2005. Hypothesis paper Brain talks with fat-evidence for a hypothalamic-pituitary-adipose axis? Neuropeptides 39: 363-367.
157. Björkstrand, E., M. Eriksson & K. Uvnäs-Moberg 1996. Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. Neuroendocrinology 63: 377-383.
158. Gimpl, G. & F. Fahrenholz 2001. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 81: 629-683.
159. Pomonis, J.D., A.S. Levine & C.J. Billington 1997. Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade of neuropeptide Y-induced feeding revealed by c-fos expression. J. Neurosci. 17: 5175-5182.
160. Beckman, T.R., Q. Shi, A.S. Levine & C.J. Billington 2009. Amygdalar opioids modulate hypothalamic melanocortin-induced anorexia. Physiol. Behav. 96: 568-573.
161. Buijs, R.M., S.E. La Fleur, J. Wortel, et al 2003. The suprachiasmatic nucleus balances sympathetic and parasympathetic output to peripheral organs through separate preautonomic neurons. J. Comp. Neurol. 464: 36-48.
162. Lechan, R.M. & C. Fekete 2006. Role of melanocortin signaling in the regulation of the hypothalamic-pituitary-thyroid (HPT) axis. Peptides 27: 310-325.
163. Singhal, N.S., M.A. Lazar & R.S. Ahima 2007. Central resistin induces hepatic insulin resistance via neuropeptide Y. J. Neurosci. 27: 12924-12932.
164. Corder, R., F. Pralong, D. Turnill, et al 1988. Dexamethasone treatment increases neuropeptide Y levels in rat hypothalamic neurones. Life Sci. 43: 1879-1886.
165. Akabayashi, A., N. Levin, X. Paez, et al 1994. Hypothalamic neuropeptide Y and its gene expression: relation to light/dark cycle and circulating corticosterone. Mol. Cell. Neurosci. 5: 210-218.
166. Apostolakis, E.M., R. Lanz & B.W. O'Malley 2004. Pituitary adenylate cyclase-activating peptide: a pivotal modulator of steroid-induced reproductive behavior in female rodents. Mol. Endocrinol. 18: 173-183.